Summary
Diamyd Inc. could have 10 new medicines ready to go at its South Oakland lab, and each could have a billion-dollar market, President Darren Wolfe said Monday. Wolfe just needs an investor.
"All we need is more cash to get this into trials," said Wolfe, who runs the University of Pittsburgh spin-off company that specializes in drugs to treat nerve damage and pain. "Currently it's very difficult because of the economic environment. Everybody we talk to is very interested. It just seems everyone is holding onto their cash."See the full content of this document
Extract
Firms Hope G-20 Wins Investors
Diamyd is one of many companies working with the Pittsburgh Life Sciences Greenhouse that hope the upcoming G-20 summit might be a springboard. Built lite...
See the full content of this document
Sponsored links
